Therefore, our study indicates MOB2 as an endogenous master upstream inhibitor in the FAK/Akt pathway in GBM cells and low levels of MOB2 protein may serve as a predictive biomarker for FAK activation and inhibitor sensitivity in GBM. The gene discussed is MOB2; the disease is glioblastoma.